{
    "nct_id": "NCT05130255",
    "official_title": "Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma",
    "inclusion_criteria": "* Signed informed consent from patient, legal guardian(s) and/or adolescents obtained in accordance with local regulations. Pediatric patients must provide assent as required by local regulations.\n* Age ≥18 years at the time of informed consent, for High Risk Neuroblastoma &amp; sarcoma age ≥16 years of age at time of informed consent/assent\n* Measurable disease according to RECIST 1.1\n* ECOG performance status 0-1\n* Expected survival &gt;3 months\n* Platelet counts ≥100,000 cells/mm3\n* Hemoglobin ≥9 g/dL\n* Adequate renal function with serum creatinine ≤1.5 mg/dL or creatinine clearance ≥60mL/min as calculated using the Cockcroft-Gault equation\n* Patient willing and able to comply with the trial protocol\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administered within 3 weeks prior to the first planned dosing of the IMP per protocol\n* Patients receiving any other investigational therapy for their cancer within 3 weeks prior to the first planned dosing of the IMP per protocol\n* Ongoing radiation toxicities from prior RT therapy\n* Patients with a diagnosis of autoimmune diseases or immunodeficiencies or documented infection with human immunodeficiency virus (HIV) or hepatitis B or C virus (active)\n* Prior treatment with anti-GD2 antibody",
    "miscellaneous_criteria": ""
}